hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-06 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Anagani Satya Prasad is cabinet Minister ( Revenue, Registration & Stamps ) & MLA of Andhra Pradesh from Repalle Constituency in Guntur district, Andhra Pradesh. He was elected to assembly elections in 2014 & 2019 defeating Mopidevi Venkata Ramana of YSRCP and in 2024 defeating Evuri Ganesh of YSRCP.
== External links == Magnesium at The Periodic Table of Videos (University of Nottingham) Chemistry in its element podcast (MP3) from the Royal Society of Chemistry's Chemistry World: Magnesium "Magnesium – a versatile and often overlooked element: New perspectives with a focus on chronic kidney disease". Clinical Kidney Journal. 5 (Suppl 1): NP. February 2012. doi:10.1093/ndtplus/sfs035. PMC 4455823. PMID 26069823. usgs.gov: Magnesium compounds and Magnesium Metal (Mineral Commodity Summaries 2025, p112-115)
In his 2011 paper Nature's Way of Making Audacious Space Projects Viable, he states that the Earth's non-renewable energy sources are nearly exhausted; natural gas will be depleted by 2020–2030, coal by 2035, uranium by 2056, while oil production peaked in 2006–2008. Nuclear energy cannot fully meet the world's energy needs (it represented only 6% in 2011). In addition, renewable energy cannot meet the growing demand for energy. Most of the minerals used by humans are in danger of becoming scarce; 11 minerals are already classified as having passed their peak production. For Metzger, humanity must therefore undertake a "100-year project" aimed at building a spacecraft ("100 Year Starship") capable of accessing the vast energy resources of the Solar System. For Metzger, it is even probable that if extraterrestrials coveted the energy resources of our Solar System, they would not look for them on Earth, but on the various asteroids and planetoids. Robotics is the only way to access so many dispersed resources, and humanity should embark on a second long-term project, which Metzger calls the "robotsphere", that would begin with the energetic exploitation of the Moon (estimated at 2.3×1012 J/year). This first step would make it possible to reach Type II in 53 years. Then the robotsphere (self-replicating and self-learning automated probes) would extend to the rest of the Solar System. Current advances in artificial intelligence suggest that the foundations of a robotsphere could be reached early in the next century, beginning in 2100.
Sources: en.wikipedia.org
Depletion of PPARG in mice results in embryonic lethality at E10.5, due to the vascular anomalies in placenta, with no permeation of fetal blood vessels and dilation and rupture of maternal blood sinuses. The expression of PPARG can be detected in mouse placenta as early as E8.5 and through the remainder of gestation; in the human placenta, PPARG is mainly located in the primary trophoblast cell. PPARG is required for epithelial differentiation of trophoblast tissue in mice, which is critical for proper placenta vascularization. PPARG agonists inhibit extravillous cytotrophoblast invasion. PPARG is also required for the accumulation of lipid droplets by the placenta in mice.
=== United States === Radiology is a field in medicine that has expanded rapidly after 2000 due to advances in computer technology, which is closely linked to modern imaging techniques. Applying for residency positions in radiology has become highly competitive. Applicants are often near the top of their medical school classes, with high USMLE (board) examination scores. Diagnostic radiologists must complete prerequisite undergraduate education, four years of medical school to earn a medical degree (D.O. or M.D.), one year of internship, and four years of residency training. After residency, most radiologists pursue one or two years of additional specialty fellowship training. The American Board of Radiology (ABR) administers professional certification in Diagnostic Radiology, Radiation Oncology, and Medical Physics as well as subspecialty certification in neuroradiology, nuclear radiology, pediatric radiology, and vascular and interventional radiology. "Board Certification" in diagnostic radiology requires successful completion of two examinations. The Core Exam is given after 36 months of residency. Although previously taken in Chicago or Tucson, Arizona, beginning in February 2021, the computer test transitioned permanently to a remote format. It encompasses 18 categories. A passing score is 350 or above. A fail on one to five categories was previously a Conditioned exam; beginning in June 2021, the conditioned category will no longer exist, and the test will be graded as a whole. The Certification Exam can be taken 15 months after completion of the Radiology residency.
The paintings of Bamiyan in northern Afghanistan are generally considered as the precussors of the art of the Kizil Caves. Towards the end of the period, the influence of the art of Gandhara is considered as a consequence of the political unification of the area between Bactria and Kucha under the Hephthalites, which lasted from 480 to 560 CE, or a few decades later.
== Bibliography == Corson, D. R.; MacKenzie, K. R.; Segrè, E. (1940). "Artificially Radioactive Element 85". Physical Review. 58 (8): 672–678. Bibcode:1940PhRv...58..672C. doi:10.1103/PhysRev.58.672. (subscription required) Greenwood, N. N.; Earnshaw, A. (2002). Chemistry of the Elements (2nd ed.). Butterworth-Heinemann. ISBN 978-0-7506-3365-9. Kugler, H. K.; Keller, C. (1985). 'At, Astatine', System No. 8a. Gmelin Handbook of Inorganic and Organometallic Chemistry. Vol. 8 (8th ed.). Springer-Verlag. ISBN 978-3-540-93516-2. Lavrukhina, Avgusta Konstantinovna; Pozdnyakov, Aleksandr Aleksandrovich (1970). Analytical Chemistry of Technetium, Promethium, Astatine, and Francium. Translated by R. Kondor. Ann Arbor–Humphrey Science Publishers. ISBN 978-0-250-39923-9. Scerri, Eric (2013). A Tale of Seven Elements. Oxford University Press, ISBN 9780195391312. Vértes, A.; Nagy, S.; Klencsár, Z. (2003). Handbook of Nuclear Chemistry. Vol. 4. Springer. ISBN 978-1-4020-1316-4. Zuckerman, J. J.; Hagen, A. P. (1989). Inorganic Reactions and Methods, Volume 3, The Formation of Bonds to Halogens (Part 1). John Wiley & Sons. ISBN 978-0-471-18656-4. Zuckerman, J. J.; Hagen, A. P. (1990). Inorganic Reactions and Methods, Volume 4, The Formation of Bonds to Halogens (Part 2). John Wiley & Sons. ISBN 978-0-471-18657-1.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.